Kisunla (donanemab) is the second in a new generation of amyloid-targeting medicines to reach the Japanese market after Eisai and Biogen's Leqembi (lecanemab), which was approved by the country's ...

Eisai makes it clear that the intention is in part to help support the rollout of Biogen-partnered Leqembi (lecanemab ... which was approved by Japan’s Ministry of Heath, Labour and Welfare ...

INmune Bio's high-upside potential with CORDStrom for RDEB and XPro for Alzheimer's, offering up to 144.8x returns. Click ...

Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...

Leqembi is an infusion therapy that targets and removes the beta-amyloid plaque that builds up in the brains of Alzheimer's patients.

Public support for Japanese Prime Minister Shigeru Ishiba's government dropped to a record low after he handed out gift ...

The U.S. Food and Drug Administration had just approved LEQEMBI® (lecanemab-irmb, 100 mg/mL, injection for intravenous use), making it the first traditionally-approved anti-amyloid AD treatment ...

Since becoming only the second Alzheimer's-modifying drug to gain American Federal Drug Administration approval in 2023, ...

Governor Dauda Lawal of Zamfara State has approved the appointment of two new Executive Secretaries to the Zamfara State Electricity Agency, ZAEA, and Zamfara Geographic Information System ...

And unlike ESPN, which has since seen its relationship with MLB dissolve, Fox will not send its announcers to Japan for this week’s Tokyo Series. The Los Angeles Dodgers and Chicago Cubs will ...